Below are the most recent publications written about "Oligodendroglioma" by people in Profiles.
-
Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C. Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget. 2017 May 30; 8(22):35523-35531.
-
Chawla S, Krejza J, Vossough A, Zhang Y, Kapoor GS, Wang S, O'Rourke DM, Melhem ER, Poptani H. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol. 2013 Aug; 34(8):1542-9.
-
Chadar?vian JP, Legido A, Halligan GE, Faerber EN, Piatt JH, Morrissette JD, Ara J, Grant ML, Katsetos CD. Cerebellar gliomatosis in a toddler: case report of a challenging condition and review of the literature. J Child Neurol. 2012 Apr; 27(4):511-20.
-
Chawla S, Oleaga L, Wang S, Krejza J, Wolf RL, Woo JH, O'Rourke DM, Judy KD, Grady MS, Melhem ER, Poptani H. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging. 2010 Jan; 20(1):3-8.
-
Luat AF, Behen ME, Juh?sz C, Sood S, Chugani HT. Secondary tics or tourettism associated with a brain tumor. Pediatr Neurol. 2009 Dec; 41(6):457-60.
-
Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol. 2009 May; 92(3):373-86.
-
Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, Lopinto J, Wolf RL, Judy K, Rosenfeld MR, Biegel JA, Melhem ER, O'Rourke DM. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg. 2007 Sep; 107(3):600-9.
-
Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia. 2006 Jul; 47(7):1237-8.
-
Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, Rodeck U. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol. 2002 Dec; 25(6):541-6.
-
Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol. 2001 Mar; 101(3):185-9.